Thymosin β4

01 · What it is

Thymosin β4 is a 43-amino-acid peptide encoded by an X-linked gene and present in most mammalian cells, where it is the most abundant member of the β-thymosin family and the principal reservoir of monomeric actin ^3,13. Unlike every other compound in this family it is not a designed molecule. It is an endogenous human protein that was found first and given a function afterwards.

It was isolated from thymic tissue in the 1970s and characterised as a putative thymic hormone, a framing that did not survive ¹. Its actual biological function was identified in 1990, when Safer and colleagues recognised that it sequesters G-actin ³. The name is a historical artefact: thymosin β4 is not a thymic hormone and has no established endocrine role.

The shape of its literature is the opposite of BPC-157’s. Thymosin β4 has a genuine clinical programme — at least eight completed human studies across cardiac, ophthalmic, dermatological and healthy-volunteer settings, including phase 1 dose-escalation with pharmacokinetics and anti-drug antibody testing, and at least 248 subjects whose enrolment can be confirmed from published reports ^{11,21,26,28,31}. It also has something no other compound in this family has: a published contradiction at its foundation. The cardiac rationale that drove most of its development rests on work reporting that thymosin β4 is essential for coronary vessel development ⁶. In 2012 a separate group produced a conditional knockout and reported the opposite — that thymosin β4 is dispensable for murine cardiac development and function ¹³.

Every human trial completed to date has been small, sponsor-designed, or short of a conventional statistical threshold on its primary comparison. That combination — real programme, real pharmacology, repeatedly inconclusive results — is what distinguishes this compound.

As of September 2026 thymosin β4 holds no marketing authorisation from any regulator.

02 · Evidence at a glance

Evidence grade

Early Clinical

Molecular identity

Endogenous 43-residue human peptide, X-linked gene ¹³

Molecular target

G-actin, via the β-thymosin/WH2 module — a binding partner, not a receptor ^2,5,9

Human subjects, confirmed enrolments

At least 248 across identified trials

Phase 1 data

Two independent programmes, 40 and 84 healthy subjects, with PK and anti-drug antibody assessment ^11,26

Randomised controlled trials

Multiple, in dry eye, neurotrophic keratopathy, venous ulcers and STEMI

Largest completed RCT

96 subjects, STEMI after primary PCI ³¹

Primary endpoint met in that trial

No — significance was seen only in a pre-specified early-treatment subgroup ³¹

Phase 3 result

18 subjects; primary healing comparison p = 0.0656 ²⁸

Foundational animal claim

Contradicted by a knockout study [6 vs 13]

Approval status

None, any jurisdiction

03 · Mechanism of action

G-actin sequestration through the WH2 module

Thymosin β4 binds actin monomers stoichiometrically and holds the bulk of the cellular monomer pool in a form unavailable for polymerisation ². Binding occurs through the β-thymosin/WH2 module, a short actin-binding motif conserved across a wide family of proteins, and changes the conformation and dynamics of the actin monomer rather than simply occluding it ^2,5. By buffering the free G-actin concentration, thymosin β4 sets the pool from which filaments elongate at their barbed ends when nucleating factors become available. This is well-characterised biophysics, and it is the only part of the mechanism that is not contested.

Why a sequestering protein is not obviously a drug

The pharmacological problem is that the same module has been shown to do more than sequester: depending on context, β-thymosin/WH2 proteins can also participate in filament growth, nucleation and severing ⁹. Reviewers writing on the family have called this the β-thymosin enigma — an abundant, well-characterised binding protein whose cellular role has proved far harder to pin down than its biochemistry ⁴. A molecule whose function is to hold a monomer pool at equilibrium does not have an obvious dose-response when supplied exogenously, and thymosin β4 has no identified cell-surface receptor. It binds a cytoplasmic protein, which raises the question every mechanistic paper on this compound has to answer and few do: how does an administered 43-residue peptide reach intracellular actin at all? The literature describes downstream effects on cell migration, angiogenesis and inflammation ¹² without resolving that step.

Cell migration, angiogenesis and the epicardium

Reported downstream effects follow from actin dynamics: promotion of cell migration, mobilisation and differentiation of progenitor cells, and new vessel formation ¹². The most influential claim came from work reporting that thymosin β4 is essential for coronary vessel development and promotes neovascularisation through the adult epicardium, which supplied the rationale for cardiac development ⁶. That claim is the one the 2012 knockout study contradicted ¹³.

ErbB2/Raf1 — a newer and more specific account

The most mechanistically concrete recent finding comes from the 2025 cardiac programme. RNA sequencing of ischaemia–reperfusion heart tissue indicated that recombinant human thymosin β4 modulates ErbB signalling; in hypoxia–reoxygenation models in HL-1 cells, neonatal mouse cardiomyocytes and H9C2 cells, it activated the ErbB2/Raf1 pathway, attenuated cardiomyocyte apoptosis and suppressed the pro-apoptotic protein Bad. Critically, the protective effect on cardiac function in mice was abolished by ErbB2 inhibition ³¹. That is a proper mechanistic test — a pathway identified, then knocked out to see whether the effect disappears — and it is the strongest piece of mechanism in this compound’s file.

Anti-inflammatory signalling

Separate work reports suppression of inflammatory signalling, including negative regulation of the NF-κB axis with reversal of glial phenotypic polarisation in a transgenic Alzheimer model ²⁵, and inhibition of TGF-β-driven fibrosis in a rat model of obstructive nephropathy ²³. Reviews treat anti-inflammatory activity as a second pillar of the mechanism alongside actin binding ^12,24,29,30. These effects are consistent across models but have not been traced to a single molecular event the way the ErbB2 finding has.

04 · Key research findings

Cardiac. The largest and most contested body of work. Reports that thymosin β4 is essential for coronary vessel development and promotes epicardial neovascularisation ⁶ were followed by a conditional knockout study reporting that it is dispensable for murine cardiac development and function ¹³. Reviews since have continued to describe reduced infarct volume and preserved cardiac function in preclinical ischaemic injury and antifibrotic effects in vitro and in animals ²⁰. In 2025 a randomised, placebo-controlled, double-blind trial in 96 patients with STEMI after primary PCI reported significantly reduced infarcted area at 90 days in the 43 patients who received their first dose within eight hours — but no significant difference in infarcted area across the trial as a whole ³¹. A separate 10-patient pilot tested thymosin β4-pretreated endothelial progenitor cells rather than the peptide alone ²¹, and a paediatric cardiac surgery trial was formally proposed in 2012 but does not appear to have reported ¹⁴.

This is the most-funded indication in the compound’s history, and after two decades it has produced one subgroup finding in fewer than 100 patients.

Ophthalmic. The most developed clinical programme. Two phase 2 randomised trials in dry eye reported improvements in signs and symptoms, one in severe disease including graft-versus-host disease and one using a controlled adverse environment model ^18,19. A phase 3 trial in neurotrophic keratopathy randomised 18 subjects: complete healing at four weeks occurred in 6 of 10 treated versus 1 of 8 on placebo, p = 0.0656 — a trend, not a result — with a significant secondary healing analysis at day 43 and significant symptom improvements ²⁸. The study was designed by employees of the sponsor developing the product ²⁸.

A phase 3 trial with eighteen participants is a phase 3 trial in name; the ophthalmic evidence is the best in the file and is still preliminary.

Skin and chronic wounds. A European prospective randomised dose-escalation study assessed topical thymosin β4 in venous ulcers for safety, tolerability and enhancement of healing, reported in two papers ^8,10, alongside a proposal for use in epidermolysis bullosa based on epithelial migration findings ⁷.

Small, early, and not followed by a definitive trial in either indication.

Neurological. Thymosin β4 improved neurological outcome in rat models of embolic middle cerebral artery occlusion in dose-response and aged-animal studies ^17,22, and reversed glial polarisation and cognitive impairment in APP/PS1 mice ²⁵.

Consistent rodent signal, no human stroke or dementia trial.

Kidney and lung. Alleviation of renal fibrosis and tubular apoptosis via TGF-β inhibition in rats ²³, with a 2023 review of glomerular biology ³⁰; and protection against monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy in mice ¹⁶.

Both are single-model findings in organs where no clinical development followed.

Oncology — a signal running the other way. Silencing the thymosin β4 gene decreased stemness and invasiveness in glioblastoma ¹⁵. That is the mirror image of a therapeutic claim: it implies endogenous thymosin β4 supports invasive and stem-like behaviour in at least one tumour type.

Nothing in the therapeutic literature engages with this finding, and it is the most important unexamined result in the file.

Healthy volunteers. Forty subjects received single intravenous doses of synthetic thymosin β4 from 42 to 1,260 mg, then the same dose daily for 14 days; adverse events were infrequent and mild to moderate, with no dose-limiting toxicity, dose-proportional exposure and an increasing half-life at higher doses ¹¹. A separate first-in-human programme gave recombinant human thymosin β4 to 54 subjects in single ascending doses from 0.05 to 25 µg/kg and 30 subjects in a 10-day multiple-dose arm, with pharmacokinetics and anti-drug antibody testing; no dose-limiting toxicities or serious adverse events, and no evidence of accumulation ²⁶.

Two independent phase 1 programmes with concordant safety findings is more than any other Family A compound has, by a wide margin.

05 · Evidence overview

06 · Safety profile

Animal data. The animal literature spans cardiac, renal, pulmonary and neurological models without reports of overt toxicity at the doses studied ^16,17,20,23. A conditional knockout mouse develops and functions normally, which is informative in both directions: it weakens the case that the peptide is essential, and it suggests that manipulating it is tolerated ¹³.

Human data. The strongest safety dataset in Family A, and it is still modest. Forty healthy subjects tolerated intravenous doses to 1,260 mg singly and daily for 14 days, with infrequent mild to moderate adverse events and no dose-limiting toxicity ¹¹. Eighty-four healthy subjects in a separate recombinant programme showed mild to moderate adverse events, no dose-limiting toxicities, no serious adverse events and no accumulation across ten days, with anti-drug antibody testing performed — the only immunogenicity assessment anywhere in this family ²⁶. The phase 3 ophthalmic trial reported no significant adverse effects across 18 subjects ²⁸.

What is genuinely unknown. Exposure beyond 14 days in healthy volunteers and 10 days in the recombinant programme; nothing longer has been reported. No reproductive or developmental data in humans, and the only prenatal work is a small animal study ²⁷. No carcinogenicity programme in any species. And one specific, serious gap follows from the biology rather than from the trials: silencing thymosin β4 reduced stemness and invasiveness in glioblastoma ¹⁵, which raises the question of what supplying it exogenously does in the presence of a tumour. No published study has addressed that, and the therapeutic literature does not cite the finding. Anti-drug antibody testing in one programme found no signal ²⁶; repeat-exposure immunogenicity over months remains untested.

07 · US regulatory status

Current as of 6 September 2026. Thymosin β4 is not approved as a drug in the United States or any other jurisdiction, and is not a controlled substance. Products containing it have been developed under investigational applications for ophthalmic and cardiac indications but none has reached authorisation ^28,31.

A regulatory distinction matters here and is routinely lost. The substance placed in category 2 of FDA’s interim bulk drug substances policy in September 2023 was “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” — the seven-residue fragment, not the full-length 43-residue peptide. As of FDA’s page dated 22 April 2026 that entry appears in the table of substances nominated but subsequently withdrawn by the nominators ³⁵. TB-500 was reviewed by FDA’s Pharmacy Compounding Advisory Committee on 23 July 2026; full-length thymosin β4 was not on that agenda ³⁶. The confusion runs into the research literature as well: a 2026 rat tendon study describing its test article as “synthetic thymosin beta-4 (TB-500)” administered the fragment, not the full-length peptide ³³.

Under the World Anti-Doping Code, growth factors affecting muscle, tendon or ligament regeneration are prohibited at all times, and substances not approved by any governmental regulatory health authority for human therapeutic use fall within category S0.

08 · Limitations of the evidence

1. The foundational cardiac claim is contradicted in the literature. Work reporting that thymosin β4 is essential for coronary vessel development ⁶ is directly opposed by a conditional knockout study reporting that it is dispensable for murine cardiac development and function ¹³. Both remain in the record. Any account of this compound that cites the first without the second is incomplete, and most do.
2. Human trials keep landing just short. The phase 3 ophthalmic trial reported p = 0.0656 on its primary healing comparison in 18 subjects ²⁸. The 2025 cardiac trial found no significant difference in infarcted area across 96 patients, with significance confined to a 43-patient early-treatment subgroup ³¹. Subgroup and secondary findings are hypothesis-generating; treating them as results is the most common error made about this compound.
3. Trial sizes are far below what the indications require. Eighteen subjects in a phase 3, 96 in the largest cardiac trial, ten in a cell-therapy pilot ²¹. Neurotrophic keratopathy is rare and small trials are defensible there; myocardial infarction is not, and a 96-patient infarct-size study cannot settle anything.
4. Sponsor involvement is close to the data. The phase 3 report discloses that the study was designed by employees of the company developing the product, with analysis by a contract research organisation ²⁸. This is disclosed and ordinary in drug development; it is still a reason to weight independent replication heavily, and there is little.
5. The route from an administered peptide to intracellular actin is unexplained. The best-characterised molecular function of thymosin β4 is binding cytoplasmic G-actin ^2,5, yet the clinical programmes administer it intravenously and topically. No published work resolves how the established mechanism accounts for the observed effects.
6. An oncology signal sits unaddressed. Gene silencing reduced stemness and invasiveness in glioblastoma ¹⁵. A peptide that promotes migration and angiogenesis has an obvious theoretical risk profile in malignancy, and the therapeutic literature does not engage with it.
7. Long-term human exposure is untested. The longest reported dosing is 14 days ¹¹. Every indication under investigation — chronic wounds, dry eye, cardiac remodelling — would require months of administration, for which there is no safety, immunogenicity or pharmacokinetic data.

09 · References

1. Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus. 1984;6(1–2):27–42.

   PMID 6087503 ↗

2. De La Cruz EM, Ostap EM, Brundage RA, Reddy KS, Sweeney HL, Safer D. Thymosin-beta(4) changes the conformation and dynamics of actin monomers. Biophys J. 2000;78(5):2516–2527.

   PMID 10777749 ↗

3. Hannappel E. beta-Thymosins. Ann N Y Acad Sci. 2007;1112:21–37.

   PMID 17468232 ↗

4. Sun HQ, Yin HL. The beta-thymosin enigma. Ann N Y Acad Sci. 2007;1112:45–55.

   PMID 17495248 ↗

5. Carlier MF, Hertzog M, Didry D, et al. Structure, function, and evolution of the beta-thymosin/WH2 (WASP-Homology2) actin-binding module. Ann N Y Acad Sci. 2007;1112:67–75.

   PMID 17947587 ↗

6. Smart N, Risebro CA, Melville AA, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci. 2007;1112:171–188.

   PMID 17495252 ↗

7. Fine JD. Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin beta4. Ann N Y Acad Sci. 2007;1112:396–406.

   PMID 17468231 ↗

8. Guarnera G, De Rosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci. 2007;1112:407–412.

   PMID 17495250 ↗

9. Husson C, Cantrelle FX, Roblin P, et al. Multifunctionality of the beta-thymosin/WH2 module: G-actin sequestration, actin filament growth, nucleation, and severing. Ann N Y Acad Sci. 2010;1194:44–52.

   PMID 20536449 ↗

10. Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207–212.

    PMID 20536470 ↗

11. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223–229.

    PMID 20536472 ↗

12. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51.

    PMID 22074294 ↗

13. Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456–464.

    PMID 22158707 ↗

14. Stromberg D, Raymond T, Samuel D, et al. Use of the cardioprotectants thymosin beta4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial. Ann N Y Acad Sci. 2012;1270:59–65.

    PMID 23050818 ↗

15. Wirsching HG, Krishnan S, Florea AM, et al. Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain. 2014;137(Pt 2):433–448.

    PMID 24355709 ↗

16. Wei C, Kim IK, Li L, Wu L, Gupta S. Thymosin beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. PLoS One. 2014;9(11):e110598.

    PMID 25412097 ↗

17. Morris DC, Cui Y, Cheung WL, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014;345(1–2):61–67.

    PMID 25060418 ↗

18. Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496.

    PMID 25826322 ↗

19. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment model. Clin Ophthalmol. 2015;9:877–884.

    PMID 26056426 ↗

20. Pipes GT, Yang J. Cardioprotection by thymosin beta 4. Vitam Horm. 2016;102:209–226.

    PMID 27450736 ↗

21. Zhu J, Song J, Yu L, et al. Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: a pilot study. Cytotherapy. 2016;18(8):1037–1042.

    PMID 27288307 ↗

22. Morris DC, Cheung WL, Loi R, et al. Thymosin β4 for the treatment of acute stroke in aged rats. Neurosci Lett. 2017;659:7–13.

    PMID 28864242 ↗

23. Yuan J, Shen Y, Yang X, et al. Thymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models. BMC Nephrol. 2017;18(1):314.

    PMID 29047363 ↗

24. Belsky JB, Rivers EP, Filbin MR, Lee PJ, Morris DC. Thymosin beta 4 regulation of actin in sepsis. Expert Opin Biol Ther. 2018;18(sup1):193–197.

    PMID 29508629 ↗

25. Wang M, Feng LR, Li ZL, et al. Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice. J Neuroinflammation. 2021;18(1):146.

    PMID 34183019 ↗

26. Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222–8228.

    PMID 34346165 ↗

27. Faa G, Piras M, Mancuso L, et al. Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery. Eur Rev Med Pharmacol Sci. 2021;25(1):431–437.

    PMID 33506933 ↗

28. Sosne G, Gross RH, Springs C, Sung J, Kang S, Kleinman HK. 0.1% RGN-259 (thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2023;24(1):554.

    PMID 36613994 ↗

29. Ying Y, Lin C, Tao N, et al. Thymosin beta4 and actin: binding modes, biological functions and clinical applications. Curr Protein Pept Sci. 2023;24(1):78–88.

    PMID 36464872 ↗

30. Mason WJ, Vasilopoulou E. The pathophysiological role of thymosin β4 in the kidney glomerulus. Int J Mol Sci. 2023;24(9):7684.

    PMID 37175390 ↗

31. Zhang Y, Dong Q, Bian X, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747–2758.

    PMID 41229390 ↗

32. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921–1935.

    PMID 41966639 ↗

33. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822–837.

    PMID 42542926 ↗

34. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026; online ahead of print.

    PMID 42578445 ↗

35. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

36. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗